NOX
NOXOPHARM LIMITED ORDINARYNoxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. The company was incorporated in 2015 and is based in Glenhaven, Australia.
NOX
NOX
NOXOPHARM LIMITED ORDINARY
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions.
Fundamentals
Historical Data42 days
| Date | Short % | Gross Short |
|---|---|---|
| 28 Aug | — | — |
| 27 Aug | — | — |
| 26 Aug | — | — |
| 25 Aug | 0.00% | — |
| 24 Aug | 0.00% | — |
| 21 Aug | — | — |
| 20 Aug | — | — |
| 19 Aug | — | — |
| 18 Aug | — | — |
| 17 Aug | — | — |
| 14 Aug | — | — |
| 13 Aug | — | — |
Noxopharm Limited (NOX) Short Interest Summary
Noxopharm Limited (NOX) currently has 0.00% of its shares sold short (4 thousand shares, worth approximately $0K), based on ASIC short position data reported on 25 August 2026 (T+4 reporting lag). That makes NOX the #631 most shorted stock on the ASX most shorted list. NOX is part of the Health Care sector on the ASX.
Recent NOX Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 25 Aug 2026 | 0.00% | 0.0M | $0.09 |
| 24 Aug 2026 | 0.00% | 0.0M | $0.09 |
| 28 July 2026 | 0.00% | 0.0M | $0.10 |
NOX Short Selling — Frequently Asked Questions
What is Noxopharm Limited (NOX)'s current short interest?
Noxopharm Limited (NOX) currently has a short interest of 0.00% of total shares outstanding. This means 0.00% of NOX's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is NOX heavily shorted on the ASX?
NOX has a relatively low short interest of 0.00%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for NOX investors?
Short interest in NOX shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 0.00%, NOX's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this NOX short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for NOX.